top of page

Targeting the 'Master Switch': How Regional Scientists Are Decoding Aggressive Breast Cancer

  • Aug 26
  • 3 min read

By Nur Khalisah



This review analyzes the article "Targeting the 'Master Switch': How Regional Scientists Are Decoding Aggressive Breast Cancer", which highlights research authored by Dr. Cai Wanpei and her team. The piece details a significant medical breakthrough by researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS), focusing on the discovery of the DP103 protein as a "master switch" in treating Triple-Negative Breast Cancer (TNBC).

 

For decades, a diagnosis of Triple-Negative Breast Cancer (TNBC) has represented one of oncology’s most stubborn barriers. Accounting for 15 to 20 percent of all breast cancer diagnoses globally, TNBC lacks the typical hormonal receptors that targeted therapies usually latch onto. As a result, patients have traditionally relied on standard chemotherapy—a blunt tool that carries heavy side effects and offers little protection against early relapse.

 

However, a recent medical milestone from the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) offers a crucial shift in this narrative. Researchers have uncovered a molecular "master switch" driving the disease, opening the door to targeted precision medicine for one of the world's most aggressive cancers.

 

[ Standard Chemotherapy ] ───► Blunts all fast-growing cells (High toxicity) [ DP103 Master Switch ]   ───► Disrupted by RX-5902 (Targeted)

│

▼

Starves Cancer Stem Cells

& Triggers Natural Cell Death

 

Unmasking the DP103 Biomarker

 

At the center of TNBC's resilience are cancer stem cells. While conventional chemotherapy often destroys bulk tumor cells, these persistent stem cells frequently survive in the background, leading to rapid recurrence and metastasis.

 

The NUS research team, led by Principal Investigator Assistant Professor Alan Prem Kumar at the NUS Centre for Cancer Research (N2CR), identified a specific master regulator protein known as DP103. DP103 feeds a self-reinforcing Wnt signaling cycle, essentially sending continuous growth signals to cancer stem cells while shielding them from treatment.

 

"Triple-negative breast cancer remains particularly difficult to treat because standard options do not work equally well for all patients," noted Associate Professor Celestial T. Yap, clinician-scientist and study co-author. "DP103 represents a critical biological vulnerability—linking tumor growth, stemness, and treatment resistance in a single target."

 

Switching Off the Circuit with RX-5902.

 

Having isolated DP103, researchers tested an investigational targeted drug called RX-5902 (Supinoxin) to evaluate whether the mechanism could be switched off. The oral therapy acts by preventing key cancer-promoting proteins (specifically \beta-catenin) from entering the cell nucleus. This action disables the growth genes, starves the cancer stem cells, and triggers apoptosis—the cell's natural self-destruction protocol.

 

In laboratory models and patient-derived organoid testing, the drug demonstrated remarkable efficacy across several critical parameters. Most notably, cancer stem cell viability dropped by 40% to 60%, tackling the root cause of relapse. Furthermore, there was exceptional progress in tumor shrinkage, where experimental models demonstrated up to a 90% reduction in overall tumor size while largely sparing healthy surrounding tissue. This targeted disruption also translated into significantly extended survival rates in treated models, with half surviving past 70 days compared to zero survival in the untreated control groups.

 

First author Dr. Cai Wanpei emphasized the targeted nature of the mechanism: "By preventing the signal from entering the nucleus, the drug switches off genes that drive cancer growth and spread without causing widespread systemic damage."

 

Moving Towards Precision Oncology

 

These promising laboratory findings carry substantial implications for the future of personalized oncology across the region. Rather than treating TNBC as a uniform disease with a one-size-fits-all chemotherapy regimen, DP103 can now be evaluated as a diagnostic biomarker. This allows future clinical trials to screen patients specifically for high DP103 levels, successfully identifying those who are most likely to benefit from targeted RX-5902 therapy.

 

Ultimately, as regional scientific institutions continue to advance high-impact medical research, the decoding of DP103 serves as a compelling example of how molecular biology is steering oncology away from broad-spectrum treatments and directly toward precision care.

 

 

References

 

Cai, W., Yap, C. T., & Kumar, A. P. (2026). DP103 acts as a master regulator of

Wnt/β-catenin signalling and stemness in triple-negative breast cancer. Cell Death & Disease, 17(8), 210–224.

 

National University of Singapore Yong Loo Lin School of Medicine. (2026, August 18). New

tumour-growth/

 

  

 
 
 

Comments

bottom of page